Highest-materiality recent filing
Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance
Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.
Tactile Medical Q4 revenue up 21% to $103.6M; acquires LymphaTech for $6.8M
Q4 2025 revenue $103.6M (+21% YoY); net income $10.6M ($0.46 diluted EPS) vs $9.7M ($0.40) in Q4 2024.
Tactile Medical Q3 net income $8.2M, revenue up 17%; raises FY guidance and authorizes $25M buyback
Q3 revenue $85.8M (+17% YoY), net income $8.2M ($0.36 diluted EPS) vs $5.2M ($0.21) in Q3 2024.
Revenue $78.9M, up 7.8% YoY, ahead of prior expectations; gross margin improved to 75% from 74%.
Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance
Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.
Tactile Medical Q4 rev $85.6M (+10%), net income $9.7M; guides FY25 rev $316-322M
Q4 total revenue $85.6M (+10% YoY); gross margin 75.2% vs 72.1% YoY.
Tactile Medical Q3 revenue up 5% to $73.1M; guides FY2024 $292-295M, authorizes $30M buyback
Q3 revenue $73.1M (+5% YoY); lymphedema +4%, airway clearance +10%.
Tactile Medical Q2 revenue $73.2M (+7% YoY); lowers FY 2024 guidance to $293-298M
Revenue of $73.2M, up 7% YoY; lymphedema product revenue +8%, airway clearance +2%.
TCMD Q1 revenue up 4% to $61.1M, net loss $2.2M; reaffirms FY2024 outlook; CEO transition
Total revenue $61.1M (+4% YoY); lymphedema +5%, airway clearance -4%.
the board of directors of Tactile Systems Technology, Inc. (the “Company”) elected Laura G. King to serve as a member of the board and fixed the size of the board at nine directors, all effective as of January 13, 2025.
Max materiality 0.80 · Median 0.70 · Most common event earnings